GlassScriptPhysician profile
Michael S Katz
NPI 1760443618
$6,945.18
in general payments reported to CMS, 2019-2025
36 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $173 · 2021: $680 · 2022: $1,082 · 2023: $1,434 · 2024: $1,240 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,685.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $809.44 | 2019-2025 | |
| Amgen INC. | $771.71 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $676.72 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $587.51 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $372.92 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $254.46 | 2020-2024 | |
| Exact Sciences Corporation | $237.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $218.47 | 2020-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.95 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.26 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $124.91 | 2020-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $106.28 | 2019-2024 | M-M-R II, Gardasil 9, Varivax |
| Novartis Pharmaceuticals Corporation | $92.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $83.70 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $72.13 | 2019-2021 | |
| Esperion Therapeutics, INC. | $47.12 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.68 | 2019-2022 | |
| Eisai INC. | $40.17 | 2021 | |
| Sanofi Pasteur INC. | $39.82 | 2023-2025 | |
| Edwards Lifesciences Corporation | $33.48 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $31.37 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $30.51 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $26.53 | 2025 | Rexulti |
| Dermira, INC. | $24.21 | 2020 | |
| Seqirus USA INC | $22.79 | 2025 | Flucelvax, Fluad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.60 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $22.42 | 2020 | |
| Dexcom, INC. | $22.06 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $19.72 | 2019 | |
| Sumitomo Pharma America, INC. | $16.31 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $16.22 | 2025 | Auvelity |
| Ibsa Pharma INC. | $15.82 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.14 | 2021 | |
| Currax Pharmaceuticals LLC | $14.91 | 2023 | Onzetra Xsail, Contrave |
| Organon LLC | $11.66 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.